Jazz to present six presentations on advancements in epilepsy outcomes

Jazz Pharmaceuticals announced that six company-sponsored Epidiolex oral solution presentations, including three late-breaking abstracts, will be shared at the upcoming 2022 American Epilepsy Society, AES, annual meeting, which will be held December 2-6, 2022, in Nashville, TN. "We understand the significant, lifelong implications of severe, childhood-onset epilepsy on both patients and their families. We continually strive to improve patient outcomes and are proud to present data that includes caregiver-reported insight into Epidiolex’s effects on seizure and non-seizure outcomes in both children and adults living with Lennox-Gastaut Syndrome and Dravet Syndrome," said Kelvin Tan, MB BCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals. "In addition, we are sharing long-term Phase 3 trial findings which demonstrate Epidiolex’s ability to reduce tuberous sclerosis complex-related seizures over the course of three years of treatment – further underscoring that Epidiolex is an important treatment option in an area with significant unmet patient need." Presentation highlights include: Two Late Breaker Abstracts Featuring Subgroup Analysis of BECOME Caregiver Survey Results: The BECOME survey is a global outcomes survey of caregivers of patients with LGS or DS that characterized and quantified the seizure and non-seizure outcomes of Epidiolex treatment. The results demonstrate that a substantial proportion of the caregivers of people with LGS or DS treated with Epidiolex reported improvements in many patients’ seizure and non-seizure outcomes, regardless of age group. Long-term Safety and Efficacy of Add-on Cannabidiol for Seizures Associated with Tuberous Sclerosis Complex: 3-Year Results From GWPCARE6 Open-Label Extension: Findings suggest that long-term, add-on Epidiolex treatment was well tolerated and demonstrated sustained reductions in TSC-associated seizures in patients for up to 156 weeks. REST LGS TOOL: The Refractory Epilepsy Screening Tool for LGS patients was designed to improve identification and treatment of patients with LGS. Using REST-LGS, this study identified that over half of the individuals without a previous LGS diagnosis should be referred for further diagnostic evaluation at a specialized epilepsy center, and further validated the REST-LGS for the identification of potential LGS patients with DRE and IDD.